Filter by country
Africa
Sao Tome and Principe
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Lesotho
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Cote d'Ivoire
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Angola
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
South-East Asia
Bangladesh
Bhutan
China
Korea, DPR
India
Indonesia
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by Category
Documents
Gavi Process Guidelines
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Russian
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
White papers
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
Annual Reports
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Board
Committee
Members

Articles (4214)

Showing 12 of 4214 View All
Showing 224 of 352 pages

Adverse events following immunisation: what are they, and when are they cause for concern?

A successful vaccine produces the best possible immune response, whilst keeping side effects to a minimum. When adverse events following immunisation (AEFIs) do occur, it is important that they are reported, especially if they are serious, even…

Pfizer’s COVID-19 vaccine may be over 90% efficacious, so what happens next?

An interim analysis of the Pfizer/BioNTech vaccine candidate suggests is more efficacious than many had dared to expect. The announcement is a welcome indication that a safe and effective COVID-19 vaccine might be within reach, but there are…

Science can give us the tools to end the pandemic, but it needs funding

Vaccines, tests and treatments, alongside well-equipped health systems, are the solutions to bringing the Covid-19 pandemic under control. But this won’t happen without urgent investment, explains Jeremy Farrar. 

Why we will always need vaccinations

Vaccination programmes have prevented millions of deaths worldwide, but their continued success relies on our continued participation.

Do mutations of COVID-19 virus in mink pose a threat to people?

With Denmark culling its entire farmed mink population following discovery of a mutated form of SARS-CoV2, are we at risk of further complications and diseases from animal-human transmission?

Coronavirus: believing in conspiracies goes hand in hand with vaccine hesitancy

While developing an effective vaccine probably won’t bring an immediate end to the pandemic, it’s clear that things can’t begin to return to normal without one. Anything that reduces a future vaccine’s effectiveness will be a problem. This…

Come together: how the fight to end polio can help the COVID-19 recovery

The world is anxiously awaiting the development of a safe and effective COVID-19 vaccine. Nearly 60 years ago, the world was also waiting in eager anticipation of a publicly available vaccine to stop a disease that was ravaging communities around…

Why understanding superspreaders could be one key way of controlling the COVID-19 pandemic

Superspreading events, where one person infects tens of others, appear to be playing an increasingly significant role in the spread of COVID-19. So what have we learned about these events and how can we stop them from fuelling the pandemic?

Gavi COVAX AMC: a shot in the arm for international cooperation

Never has the development of vaccines been so widely anticipated as for COVID-19, and arguably never has so much been at stake. Because without COVID-19 vaccines, we cannot bring this crisis to a swift end.

How does COVID-19 trigger a loss of smell and other olfactory disorders?

Anosmia is the medical term for a sudden loss of smell and has been associated with COVID-19. Here’s a closer look at the olfactory dysfunctions linked to the SARS-CoV-2 virus.

Nigeria is polio-free. What next?

Throughout the country, all year-round, routine and supplementary immunisation activities took place to ensure that no child was left behind from being vaccinated.

How deliberately infecting volunteers with COVID-19 could help accelerate vaccine development

Josh Morrison, Co-founder and Executive Director of 1Day Sooner, an organisation that advocates on behalf of challenge trial volunteers, explains why.

Subscribe to our newsletter